RxDoctor Payments Data

David Nichols, MD

Undersea and Hyperbaric Medicine · San Angelo, TXNPI 1003951245

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Smith+Nephew at 33.6% of the total. Reporting peaked in 2021 at $370 and has fallen 63.7% since, to $134 in 2025.

$1,583in general payments, 2019–2025

Across 70 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$532
  • Solventum Corporation$197
  • AbbVie$191
  • KCI USA, Inc.$156
  • Acera Surgical, Inc.$132
  • Organogenesis Inc.$113
  • plus $262 from 7 others

What the payments were for

  • Food & beverage$1,583100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew31$532
Solventum Corporation4$197
AbbVie(2 entities)8$191
KCI USA, Inc.4$156
Acera Surgical, Inc.1$132
Organogenesis Inc.6$113
Tactile Systems Technology Inc8$111
Melinta Therapeutics, LLC2$37
Urgo Medical North America, LLC2$31
Integra Lifesciences Corporation1$29
Cashflow Solutions, LLC1$23
Reapplix Inc.1$18
Hydrofera LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,583 in reported general payments places this provider in the 55th percentile of 59 undersea and hyperbaric medicine providers in Texas.

See all undersea and hyperbaric medicine providers in Texas

Medicare billing

Part B allowed, 2024
$251,332
Medicare patients
428
Services billed
3,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gentamicin Sulfate52$2,573
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam12$2,280
Doxycycline Hyclate155$1,547
Nystatin86$1,275
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen98$807
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav38$374
Doxycycline Monohydrate30$370
Triamcinolone Acetonide55$355
Ampicillin Trihydrate16$220
Cefdinir18$195
Ciprofloxacin Hcl15$137
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide11$123
Alprazolam13$100
Clindamycin Hcl11$82
Metformin Hcl11$76

Paid to pharmacies, not to this prescriber.

Other undersea and hyperbaric medicine in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →